<DOC>
	<DOCNO>NCT02758223</DOCNO>
	<brief_summary>PACT non-randomized multicentre phase I/II study evaluate feasibility safety prophylactic administration donor derive TCM . Patients Acute Myeloid Leukemia ( AML ) Myelodysplastic Syndrome ( MDS ) plan undergo HLA -matched ( 9/10 10/10 ) allogeneic hematopoietic stem cell transplantation either 50+ year old high comorbidity score include accord criterion describe . TCM apply escalate dos maximum 30 patient receive T cell deplete Human leukocyte antigen ( HLA ) -matched alloHSCT graft qualify TCM transfer .</brief_summary>
	<brief_title>Prophylactic Application Donor-derived TCM After Allogeneic HSCT</brief_title>
	<detailed_description>One major challenge field allo-SCT find balance harmful induction graft-versus-host disease ( GVHD ) beneficial graft-versus-leukemia ( GVL ) response , mediate donor T cell recognize antigen express cell recipient . Complete removal T cell graft result abrogation severe GVHD , also frequently associate removal immunity infectious agent anti-tumor efficacy ( GVT effect ) , reflect increased incidence infectious complication ( early ) disease relapse T cell deplete allo-SCT . The investigator hypothesize prophylactic adoptive transfer donor-derived central memory T cell safe tolerable method improve overall survival HSCT . TCM administer escalating dos day 30 , day 60 day 90 posttransplant prevent infectious complication early relapse disease progression .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Patient Male female patient Hematopoietic Cell TransplantComorbidity Index ( HCTCI ) score ( Sorror ) ≥3 AND/or Age 50 year old Primary secondary AML Month 0 , Month 1 , Month 2 , Month 4 , Month 5 , Month 6 Month 7 , Complete Remission ( CR ) ( &lt; 5 % blast bone marrow ( BM ) ) irrespective cytogenetic molecular risk profile MDS Refractory anemia excess blast 2 ( RAEB2 ) ( maximal 20 % blast bone marrow ) Planned alloHSCT Cluster Differentiation 34+ ( CD34+ ) purify stem cell graft condition fludarabinemelphalanthiothepaATG ( ATG=Antithymocyte globulin ) HLAmatched stem cell donor ( 910/10 , maximal 1 allel antigen mismatch allow ) without aberrant CD45RA ( =Cluster Differentiation ) expression Additional patient inclusion criterion : Treatment phase patient day 30 +/5 alloHSCT : Stable engraftment allogeneic graft ( granulocytes &gt; 0.5*109/L ) Donor Donor must meet requirement European Union ( EU ) Tissue Cells Directive ( 2004/23/EC ) ( see ) Healthy donor pass medical examination stem cell donation Donor must fulfill requirement allogeneic donor blood test accord Richtlinie zur Herstellung und Anwendung von hämatopoetischen Stammzellzubereitungen ( SCRichtlinie ( RILI ) der Bundesärztekammer ; 08/2014 ) Donor informed consent additional nonmobilized apheresis Written inform consent patient Patient Diseasespecific treatment foreseen first 6 month alloHSCT Patients AML M3 Pregnant lactate woman Severe psychological disturbance Positive serology Human immunodeficiency virus ( HIV ) , Syphilis , West Nile Virus ( WNV ) Participation another interventional clinical trial within 4 week study entry Additional patient exclusion criterion : Treatment phase patient day 30 +/5 alloHSCT : Disease specific treatment foreseen first 6 month alloHSCT Acute GVHD &gt; grade I immune suppressive treatment give Progressive disease therapy need Use &gt; 0,5 mg/kg bw prednisone day Life expectation &lt; 12 week End stage irreversible multisystem organ failure Donor Donor pregnant lactating Donors aberrant CD45RA isoform expression General exclusion criterion stem cell donation</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>